Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Neurocrine Biosciences Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.75 (market cap $141.25M), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 101.7× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is more actively traded (5,492,367 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Neurocrine Biosciences Inc for 23 Days on average.
| KOLD | NBIX | |
|---|---|---|
Market Cap | $141.25M | $14.36B |
Volume | 5,492,367 | 1,237,180 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $185.50 |
52-Week Low | $13.58 | $123.10 |
Typical Hold Time | 10 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $25.68, up 3.38% today, but faces bearish technical signals with 15 sell indicators versus 2 buy signals. The stock shows neutral momentum oscillators while moving averages signal strong bearish pressure. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy commodities. Support levels at $23-25 provide near-term downside protection.
The bearish technical setup and natural gas market headwinds suggest cautious near-term outlook. Investment opportunity exists if the stock holds above key support levels amid energy market volatility. Primary risks include sustained natural gas price pressure and production oversupply concerns that could impact energy sector performance.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with technical indicators showing a bearish trend despite strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.85 significantly exceeding expectations of $1.85. Revenue growth remains strong, projected to increase from $2.9B in 2025 to $3.4B in 2026, while net profit margins expanded from 16.73% to 20.91%.
Wall Street maintains strong bullish sentiment with 86% buy ratings and a $204.18 consensus price target, representing 45% upside potential. Key risks include execution challenges with the expanding product portfolio and potential pricing pressure on INGREZZA ahead of 2029 patent considerations. The technical bearish signal contrasts with fundamental strength, creating potential entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
